Arrowstreet Capital
MRKR icon

Arrowstreet Capital’s Marker Therapeutics MRKR Stock Holding History

Arrowstreet Capital’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,185
Closed -$351K – 2016
2019
Q4 		$351K Buy
12,185
+5,220
+75% +$190K ﹤0.01% 1548
2019
Q3 		$356K Buy
6,965
+50
+0.7% +$2.96K ﹤0.01% 1390
2019
Q2 		$548K Buy
6,915
+1,917
+38% +$114K ﹤0.01% 1164
2019
Q1 		$330K Buy
+4,998
New +$292K ﹤0.01% 1568

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VWM
Vigilare Wealth Management Scottsdale, Arizona $326M AUM 21.58% 1-Year Est. Return

Arrowstreet Capital's MRKR Position: Q1 2020 in Review

Arrowstreet Capital sold out of Marker Therapeutics (MRKR) in Q1 2020, closing a stake of 12,185 shares — an estimated $351K sold.

Arrowstreet Capital first reported a position in MRKR in Q1 2019 and held it in 4 quarters. The position peaked at $548K in Q2 2019. 65 funds tracked by Wall St. Rank hold MRKR as of Q1 2020.

  • Arrowstreet Capital reported no remaining Marker Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 12,185 Marker Therapeutics shares in Q1 2020, an estimated $351K.
  • Arrowstreet Capital first reported a position in Marker Therapeutics in Q1 2019 and held it in 4 quarters.
  • Arrowstreet Capital's Marker Therapeutics position peaked at $548K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.